EFFICACY OF ANTIHYPERGLYCEMIC THERAPIES AND THE INFLUENCE OF BASELINE HEMOGLOBIN A(1C): A META-ANALYSIS OF THE LIRAGLUTIDE DEVELOPMENT PROGRAM Article

Industry Collaboration International Collaboration

cited authors

  • Henry, Robert R., Buse, John B., Sesti, Giorgio, Davies, Melanie J., Jensen, Klaus H., Brett, Jason, Pratley, Richard E.

funding text

  • We thank Ashwini Dhume, PhD, and Irina Nayvelt, PhD, from Novo Nordisk, for medical writing support and editorial assistance, respectively. We gratefully acknowledge statistical and programming support provided by Helle Hartvig, MSc. Dr. Robert R. Henry has participated in advisory panels for Amylin, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Intarcia, Eli Lilly, Merck, Novo Nordisk, Roche, sanofi-aventis, and Tethys. He has been a consultant for Amgen, Boehringer Ingelheim, Dainippon Sumitomo, Isis, Novo Nordisk, Roche, sanofi-aventis, Takeda, Tethys, and Versartis and has received research support from Amylin, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, and Novartis. Dr. John B. Buse is a consultant or investigator under contract with the University of North Carolina with multiple companies, which provide no direct financial benefit to him. They include Amylin, Bayhill, BD Research Laboratories, Bristol-Myers Squibb, Intuity Medical, Johnson & Johnson, Eli Lilly, Medtronic, Inc., Merck, Novartis, Novo Nordisk, Osiris, Pfizer, Roche, sanofi-aventis, Transition Therapeutics, and Wyeth. Dr. Melanie J. Davies has participated in advisory panels/speakers' bureaus and has been a consultant for and/or received research support from GlaxoSmithKline, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, sanofi-aventis, and Servier; she holds stock from sanofi-aventis.

abstract

  • Objective: To compare liraglutide versus common antihyperglycemic treatments in reducing hemoglobin A(1c) (A1C) values across multiple levels of baseline glycemic control and in reaching glycemic targets. Methods: Pooled patient data from 7 phase 3, multinational, randomized controlled trials in patients with type 2 diabetes were stratified by baseline A1C values. into 5 categories: <= 7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and >9.0%. The changes in A1C from baseline to week 26 of treatment and patient proportions reaching A1C targets of <7.0% and <= 6.5% were compared between liraglutide (1.8 mg daily) and sitagliptin, glimepiride, rosiglitazone, exenatide, and insulin glargine across all baseline A1C categories. Results: Irrespective of treatment, reductions in A1C levels were generally greater in groups with higher baseline A1C values. After 26 weeks of treatment, liraglutide produced the greatest reductions in A C values across all baseline categories, ranging from 0.7% to 1.8% (baseline A1C categories <= 7.5% to >9.0%, respectively), followed by insulin glargine (0.3% to 1.5%) and then by glimepiride (0.4% to 1.3%): Generally, larger percentages of patients achieved the A1C target of <= 6.5% with liraglutide therapy across all baseline categories (from 62% of patients with A1C values <= 7.5% to 10% of patients with A1C values >9.0%) in comparison with other treatments (ranging from 49% to 0% of patients, respectively). Similarly, greater proportions of patients also reached the A1C target of <7.0% with liraglutide therapy across all baseline categories (from 83% of patients with A1C values <= 7.5% to 25% of patients with A1C values >9.0%) versus comparators (from 74% to 5% of patients, respectively). Conclusion: Across a wide spectrum of baseline A1C categories, liraglutide is an efficacious treatment option for patients with type 2 diabetes. (Endocr Pract. 2011;17: 906-913)

authors

Publication Date

  • November 1, 2011

webpage

published in

category

start page

  • 906

end page

  • 913

volume

  • 17

issue

  • 6

WoS Citations

  • 30

WoS References

  • 19